BAY 869596

Drug Profile

BAY 869596

Alternative Names: (d)-(18)F-fluoromethyltyrosine; (d)-18F-fluoromethyltyrosine; 18F DFMT; BAY-86-9596; d 18F FMT; D-18F- fluoromethyl tyrosine; D-18F-FMT; D-FMT; O-([18F]fluoromethyl)-D-tyrosine

Latest Information Update: 13 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Inflammation; Solid tumours

Most Recent Events

  • 13 Nov 2014 Phase I development is ongoing in Switzerland, Netherlands and Singapore
  • 13 Nov 2014 BAY 869596 is available for licensing as of 13 Nov 2014. http://piramal.com/piramal-enterprises/piramal-capital
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top